CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in difficult-to-treat cancer types. The company has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as a safe and efficacious immune therapy for solid tumors. GDF-15, an immunosuppressant important for feto-maternal tolerance, is hijacked by cancer cells to evade an immune system attack. Visugromab, CatalYm’s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment.